Key result
AF in Brugada syndrome linked to a malignant course with more syncope and ventricular arrhythmias.
Why the study?
The true prevalence of AF in Brugada syndrome remains unknown, and its mechanisms, prognostic implications, and optimal management require clarification.
Atrial fibrillation in Brugada syndrome acts as a marker of more advanced disease and is associated with a higher risk of syncope and ventricular arrhythmias.
AF may mark higher-risk Brugada syndrome warranting closer surveillance; leaves open optimal management strategies pending prospective studies.
The incidence of atrial fibrillation (AF) in Brugada syndrome (BrS) has been reported at between 9% and 53% by different series, but the true prevalence is unknown. However, AF may be the presenting feature in some patients. The underlying mechanisms for AF may be a combination of multiple factors, genetic or acquired, that may impact upon autonomic function, atrial structure, and conduction velocities or other unknown factors. The presence of AF has been associated with a more malignant course, with a greater incidence of syncope and ventricular arrhythmias, thus acting as marker of more advanced disease. Regarding the management of patients with AF, antiarrhythmic drugs effective in preventing malignant arrhythmias in BrS such as quinidine or invasive treatment with pulmonary vein isolation (PVI) may be useful in AF treatment. In this review, we aim to present the current perspectives regarding the genetics, pathophysiology, management, and prognosis of AF in patients with BrS.
No takes yet. Share an insight, caveat, or question.
Vlachos et al. (2020) conducted a review in Atrial fibrillation in Brugada syndrome. Atrial fibrillation in Brugada syndrome has a reported incidence of 9% to 53% and is associated with a more malignant course, including a greater incidence of syncope and ventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: